Genmab
GMAB
204 hedge funds and large institutions have $1.3B invested in Genmab in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 75 increasing their positions, 83 reducing their positions, and 26 closing their positions.
8,410% more call options, than puts
Call options by funds: $851K | Put options by funds: $10K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 83
1.07% less ownership
Funds ownership: 60.53% → 59.46% (-1.1%)
3% less funds holding
Funds holding: 211 → 204 (-7)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
18% less capital invested
Capital invested by funds: $1.58B → $1.3B (-$282M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$13.1M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$11.6M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$9.71M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.3M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$5.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$26.2M |
| 2 |
Goldman Sachs
New York
|
-$18.5M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$8.39M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.38M |
| 5 |
F
Folketrygdfondet
Oslo Norway,
Norway
|
-$4.55M |
GMAB Hedge Fund Activity: Q1 2022 in Review
204 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2022, worth a combined $1.3B — down 18% from $1.58B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of GMAB and 22 opened new positions — a net loss of 4 holders — while 83 trimmed existing stakes and 75 added.
The largest buyer was American Century Companies, adding an estimated $13.1M. The largest seller was Redmile Group, exiting entirely with an estimated $26.2M sold.
- 204 institutional investors held Genmab (GMAB) as of Q1 2022, down from 211 in Q4 2021.
- Funds reported $1.3B of Genmab stock for Q1 2022, down 18% quarter-over-quarter.
- 22 funds opened new Genmab positions in Q1 2022 and 26 closed out, a net change of -4 holders.
- The largest Genmab buyer in Q1 2022 was American Century Companies, an estimated $13.1M added.
- The largest Genmab seller in Q1 2022 was Redmile Group, an estimated $26.2M sold.
Based on aggregated 13F filings for Q1 2022.